Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast Cancer
October 21st 2023
Francisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.